Massachusetts can expect the wintertime chorus of hacking coughs and sniffling to continue as Respiratory Syncytial Virus and ...
New data reveals that Montana is among the top states in the nation for protecting infants from Respiratory Syncytial Virus ...
Data shows that ER visits and hospital admissions for RSV have been climbing in New Jersey since early October. Currently, ER ...
This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. While pregnant with her third child ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Health Canada has approved ENFLONSIA® (clesrovimab) for the prevention of respiratory syncytial virus (RSV) ...
The study included 31,900 infants, 49.1% of whom received nirsevimab. HealthDay News — Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower ...
(CNN) — The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants. The US Food and Drug ...
Add Yahoo as a preferred source to see more of our stories on Google. The season of never-ending sneezing and stuffy noses is underway, sending Americans to pharmacy lines in hopes of keeping illness ...
Each winter, worried parents have flooded health care providers’ offices with sick babies, hoping for treatment that could help their infant recover from this “stubborn cold.” Many parents don’t ...
Merck (NYSE:MRK) received Health Canada approval for ENFLONSIA® (clesrovimab) for RSV prevention in newborns and infants. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results